Context
The market of therapeutic monoclonal antibodies (mAbs) is on the rise :
Technology
The technology consists in developing mAbs with a Fc fragment of the Asian allotype. This results in an increased binding to FcRn receptor of endothelial cells compared to caucasian allotype-based mAbs. This receptor modulates the biodistribution and halflife of antibodies. With the Asian allotype, the binding of mAbs to FcRn receptor is increased by 10% and the stability of this binding is improved by about 40%. Consequently therapeutic antibodies developed with Asian allotype should display a longer half-life in both caucasian and Asian patients:
- Caucasian : better affinity for FcRn receptor than endogen antibodies.
-Asian : No unfavorable competition with endogen antibodies for binding FcRn.
Competitive advantage